Sorrento Therapeutics, Inc. (SRNE) Bundle
Ever wondered about the journey of a biopharmaceutical company dedicated to developing innovative therapies for critical illnesses? Sorrento Therapeutics, Inc. (SRNE), a clinical and commercial-stage company, has been making strides in the healthcare sector, particularly in cancer, pain management, and infectious diseases. But how exactly does this antibody-centric company operate, and what's its strategy for generating revenue in such a competitive market? Keep reading to find out!
Sorrento Therapeutics, Inc. (SRNE) History
Sorrento Therapeutics Founding Timeline
Year established
Sorrento Therapeutics was established in 2006.
Original location
The company was originally located in San Diego, California.
Founding team members
Details on the specific founding team members are not readily available in the search results. However, it is known that Henry Ji has been a key figure in the company's leadership, serving as Chairman, President, and CEO.
Initial capital/funding
Information regarding the initial capital or funding is not available in the provided search results.
Sorrento Therapeutics Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2009 | Acquisition of Antitope Ltd. | Expanded Sorrento's antibody development capabilities, particularly in the area of humanizing antibodies. |
| 2012 | Acquisition of BioBest GmbH | Enhanced Sorrento’s ability to produce and develop biosimilars and biobetters. |
| 2013 | Collaboration with Mount Sinai Hospital | Focused on developing new antibody therapeutics for treating cancer. |
| 2015 | Acquisition of IgDraxis, Inc. | Strengthened Sorrento's position in the antibody therapeutics field. |
| 2020 | Focus on COVID-19 therapies | Shifted focus to developing therapies and vaccines to combat the COVID-19 pandemic, including antibody therapies. |
| 2023 | Filing for Chapter 11 bankruptcy | Filed for Chapter 11 bankruptcy protection to reorganize and address financial challenges. |
Sorrento Therapeutics Transformative Moments
- Strategic Acquisitions: Sorrento has grown through strategic acquisitions, enhancing its capabilities in antibody development, biosimilars, and cancer therapies.
- Focus on COVID-19: The company's pivot to developing COVID-19 therapies and vaccines marked a significant shift in its strategic focus.
- Bankruptcy Filing: The Chapter 11 filing in 2023 represents a transformative moment, as the company seeks to restructure its finances and operations.
- Leadership of Henry Ji: Henry Ji's role as Chairman, President, and CEO has been central to the company's strategic direction and evolution.
For insights into the company's financial standing, consider reading: Breaking Down Sorrento Therapeutics, Inc. (SRNE) Financial Health: Key Insights for Investors
Sorrento Therapeutics, Inc. (SRNE) Ownership Structure
Sorrento Therapeutics operates with a mixed ownership structure, featuring a combination of institutional, retail, and insider stakeholders who influence its strategic direction and corporate governance.
Sorrento Therapeutics, Inc. Current Status
Sorrento Therapeutics, Inc. is currently a public company, trading under the ticker symbol SRNE. However, it is important to note that the company filed for Chapter 11 bankruptcy in February 2023. As of late 2024 and early 2025, Sorrento is working through its bankruptcy restructuring process, aiming to emerge with a sustainable financial footing. This process involves significant negotiations with creditors and could potentially lead to changes in the company's ownership structure as part of the reorganization plan. For more insights, you might find this resource helpful: Breaking Down Sorrento Therapeutics, Inc. (SRNE) Financial Health: Key Insights for Investors.
Sorrento Therapeutics, Inc. Ownership Breakdown
The ownership of Sorrento Therapeutics is distributed among various types of shareholders. Here's an approximate breakdown based on the latest available data:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | Approx. 45-55% | Includes investment firms, hedge funds, and mutual funds. These entities often have significant influence due to the size of their holdings. |
| Retail Investors | Approx. 35-45% | Represents individual investors who hold shares. This segment can be more volatile and less coordinated in influencing company decisions. |
| Insiders (Executives and Board Members) | Approx. 5-10% | Shares held by key executives and board members. Their ownership is closely watched as it aligns their interests with the company's performance. |
Sorrento Therapeutics, Inc. Leadership
As of April 2025, the leadership team guiding Sorrento Therapeutics includes:
- Chairman and CEO: The specific individual holding this position may have changed due to the bankruptcy proceedings. It is essential to consult the latest company announcements for the most current information.
- Chief Financial Officer (CFO): Oversees the company's financial strategy and reporting, crucial during the restructuring phase.
- Chief Scientific Officer (CSO): Leads the research and development efforts, focusing on advancing Sorrento's pipeline of therapeutic candidates.
- Board of Directors: The board plays a critical role in overseeing the company's management and strategic direction, especially during the bankruptcy process. Changes to the board composition may occur as part of the restructuring.
The leadership team is focused on navigating the company through its Chapter 11 proceedings, with the goal of emerging as a stronger, more sustainable entity. Strategic decisions are heavily influenced by the need to satisfy creditor obligations and secure long-term funding for research and development initiatives.
Sorrento Therapeutics, Inc. (SRNE) Mission and Values
Sorrento Therapeutics aims to improve the lives of patients and create value for its stakeholders through innovative therapies. The company's values are centered around scientific innovation, patient-centricity, and integrity.
Sorrento Therapeutics' Core Purpose
Official mission statement
Sorrento Therapeutics' mission statement, as reflected in various communications and filings, centers on:
- Developing new therapies to improve the lives of patients, especially those suffering from severe, unmet medical needs.
- Focusing on pain management, cancer, and infectious diseases.
- Creating a pipeline of innovative products through research and development.
Vision statement
While a specific, formally declared vision statement may not be explicitly publicized, Sorrento Therapeutics' vision can be inferred from its strategic goals and activities:
- To become a leading biopharmaceutical company recognized for its novel approaches to treating critical illnesses.
- To deliver breakthrough treatments that significantly enhance patient outcomes and quality of life.
- To build a sustainable and valuable enterprise through innovation, strategic partnerships, and operational excellence.
Company slogan/tagline
Sorrento Therapeutics has used several taglines and slogans in its communications, reflecting its focus and goals:
- 'Innovating to Live' – captures the essence of their commitment to pioneering medical advancements.
- Other messaging emphasizes their focus on 'breakthrough therapies' and 'addressing unmet needs,' highlighting their dedication to solving significant medical challenges.
To delve deeper into Sorrento Therapeutics, Inc. (SRNE), consider exploring this resource: Exploring Sorrento Therapeutics, Inc. (SRNE) Investor Profile: Who’s Buying and Why?
Sorrento Therapeutics, Inc. (SRNE) How It Works
Sorrento Therapeutics, Inc. operates as a biopharmaceutical company focused on the development of new therapies to treat cancer, pain, and other diseases.
Sorrento Therapeutics, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| G-MAB™ library | Pharmaceutical companies and research institutions | A vast collection of fully human antibodies for therapeutic antibody discovery. |
| Sofusa® platform | Patients with solid tumors | A drug delivery system designed to improve the penetration of therapeutics into solid tumors. |
| Resiniferatoxin (RTX) | Patients with intractable cancer pain | A potent TRPV1 agonist for the treatment of severe pain. |
Sorrento Therapeutics, Inc.'s Operational Framework
Sorrento Therapeutics, Inc. focuses on several operational processes to drive value creation:
- Research and Development: Investing in the discovery and preclinical/clinical development of novel therapeutic candidates.
- Strategic Partnerships: Collaborating with other pharmaceutical companies and research institutions to expand the pipeline and accelerate drug development.
- Intellectual Property: Protecting its innovations through patents and other intellectual property rights.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Manufacturing: Managing the manufacturing process to ensure the availability of drug supplies for clinical trials and potential commercialization.
Sorrento Therapeutics, Inc.'s Strategic Advantages
Sorrento Therapeutics, Inc. maintains several competitive advantages in the biopharmaceutical industry:
- Innovative Technology Platforms: Proprietary platforms like the G-MAB™ library and Sofusa® drug delivery system provide a competitive edge in developing new therapies.
- Diverse Pipeline: A broad portfolio of drug candidates targeting various diseases reduces the risk associated with relying on a single product.
- Experienced Management Team: A team of experienced professionals in drug development and commercialization guides the company's strategic direction.
- Strategic Collaborations: Partnerships with other companies and research institutions provide access to additional resources and expertise.
To gain more insights into the company's values, refer to this link: Mission Statement, Vision, & Core Values of Sorrento Therapeutics, Inc. (SRNE).
Sorrento Therapeutics, Inc. (SRNE) How It Makes Money
Sorrento Therapeutics, Inc. primarily focuses on the discovery, development, and commercialization of innovative therapies for pain management and cancer. Revenue generation is achieved through a combination of product sales, licensing agreements, and strategic collaborations.
Sorrento Therapeutics, Inc. Revenue Breakdown
As a note, it is difficult to provide an exact revenue breakdown for the trailing twelve months (TTM) ending in April 2025. The latest complete fiscal year data available is for 2024. Please refer to the latest financial filings for the most up-to-date information.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Product Sales (Pain Management) | ~65% | Increasing |
| Licensing and Collaboration Agreements | ~35% | Variable |
Sorrento Therapeutics, Inc. Business Economics
Sorrento Therapeutics, Inc.'s business economics are shaped by several key factors:
- Research and Development (R&D) Investment: A significant portion of their expenditure is allocated to R&D, essential for developing new therapies and expanding their product pipeline.
- Intellectual Property: Protecting their innovations through patents and proprietary rights is crucial for maintaining a competitive advantage and securing future revenue streams.
- Strategic Partnerships: Collaborations with other pharmaceutical companies and research institutions can provide access to additional resources, expertise, and markets.
- Regulatory Approvals: The ability to navigate the regulatory landscape and secure approvals for their products is vital for commercial success.
Sorrento Therapeutics, Inc. Financial Performance
Analyzing Sorrento Therapeutics, Inc.'s financial performance involves looking at these key areas:
- Revenue Growth: Monitoring the growth in product sales and licensing revenue indicates the company's ability to commercialize its products and form successful partnerships.
- Gross Margin: Evaluating the gross margin helps assess the profitability of its products and the efficiency of its manufacturing processes.
- Operating Expenses: Analyzing operating expenses, including R&D and SG&A, provides insights into the company's investment in future growth and its operational efficiency.
- Cash Flow: Tracking cash flow from operations, investing, and financing activities reveals the company's ability to fund its operations, invest in new opportunities, and manage its debt.
To gain more insights into the financial health of Sorrento Therapeutics, Inc., you can explore this resource: Breaking Down Sorrento Therapeutics, Inc. (SRNE) Financial Health: Key Insights for Investors
Sorrento Therapeutics, Inc. (SRNE) Market Position & Future Outlook
Sorrento Therapeutics is navigating a dynamic biopharmaceutical landscape, striving to solidify its position through strategic initiatives and innovative therapies. The company faces both significant opportunities and considerable challenges as it aims to deliver value to shareholders and improve patient outcomes.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Sorrento Therapeutics | Estimated at less than 1% (Niche player with focus on pain management and oncology) | Proprietary drug development platforms, including antibody and cell-based therapies. |
| Johnson & Johnson | Approximately 15-20% (Diversified healthcare giant) | Extensive product portfolio, global reach, and strong financial resources. |
| Pfizer | Approximately 12-18% (Leading pharmaceutical company) | Robust research and development pipeline, established market presence, and diverse therapeutic areas. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancing clinical programs in pain management and oncology, particularly resiniferatoxin (RTX) for intractable pain. | Dependence on successful clinical trial outcomes and regulatory approvals. |
| Leveraging proprietary platforms to develop novel therapies and expand the product pipeline. | Intense competition from larger pharmaceutical companies with greater resources. |
| Strategic collaborations and partnerships to accelerate drug development and commercialization. | Financial constraints and the need for additional funding to support operations. |
Industry Position
Sorrento Therapeutics operates within the highly competitive biopharmaceutical industry. Here are some key points regarding their position:
- Niche Player: Sorrento occupies a niche position, focusing on specific therapeutic areas like pain management and oncology.
- Innovation Focus: The company emphasizes innovative drug development, utilizing its proprietary platforms to create novel therapies.
- Development Stage: Sorrento is largely a development-stage company, meaning its value is heavily tied to the success of its clinical programs.
To gain further insights into the company's core values and strategic vision, explore: Mission Statement, Vision, & Core Values of Sorrento Therapeutics, Inc. (SRNE).
Sorrento Therapeutics, Inc. (SRNE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.